HGSI also has rights to improvements in Dyax' phage display technology. We believe that Dyax is one of the leading companies in phage display technology. This technology represents a natural extension of our focus on the pharmaceutical potential of human secretory proteins. HGSI has developed leadership in the isolation and characterization of these medically interesting proteins. These secretory proteins, we believe, comprise the great majority of peptide hormones, receptors, ion channels, and transporters.
Some secretory proteins are useful as drugs themselves.
HGSI is not only a leader in genomics based protein drug discovery, it has now acquired considerable capabilities in human antibody based drug discovery and peptide based drug discovery. We intend to develop, manufacture and sell all three types of drugs. In addition, HGSI's ability to provide intellectual property protection of its human proteins used as drugs themselves or as targets for human antibody and peptide drugs should be attractive to our present partners and future collaborators. Any statements released by Human Genome Sciences, Inc. that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that forward looking statements involve risks and uncertainties which may affect the company's business prospects and performance.